The pembrolizumab regimen reduced the risk of disease progression or death by 28% and reduced the risk of death by 24% compared with placebo plus paclitaxel with or without bevacizumab. The Food and ...
Overall survival data showed a 50% reduction in the risk of death with the regimen compared with surgery alone. The approval was supported by data from the open-label, phase 3 KEYNOTE-905/EV-303 study ...
The FDA approved pembrolizumab (Keytruda) plus paclitaxel for recurrent ovarian cancers that express PD-L1, the agency announced on Tuesday. Approval stipulates use of the combination, with or without ...
EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results